Event Date/Time: May 02, 2012
End Date/Time: May 03, 2012
Bispecific and multiclonal antibodies are one of the most promising and exciting areas of protein engineering. Since 2009, there have been deals made in excess of $6.5 billion on bispecifics, and the range of therapeutic uses for bispecific antibodies are being expanding beyond oncology to diseases of the immune system, heart and CNS. This meeting will explore the remaining challenges and profile creative problem solving that has been used to make successful bispecific formats. The latest approaches for dual-targeting as well as targeting two different epitopes of the same receptor will be explored for improving efficacy.